Chi Steve Chan – Chairman & CEO, Adimmune Corporation, Taiwan
Adimmune Corporation is the only influenza vaccine manufacturer with both EU GMP and US FDA certification in Asia, as well as the only PIC/S GMP manufacturer of human vaccines in…
Founded in 22nd December 1965, Adimmune Corporation principally engages in R&D, manufacture and sale of vaccines and medicines. Production base is in Tanzi, Taichun. The important well-known product is H1N1 vaccine. IPO issued in Forth January 2010. Our main product is the influenza vaccine. The main product of this company, influenza vaccine, is provided to public in Taiwan by Sanofi-Aventis, Novartis and Glaxo Smith Kline (GSK). Major raw materials are the liquid, syringes, and mice.
Adimmune Corporation is the only influenza vaccine manufacturer with both EU GMP and US FDA certification in Asia, as well as the only PIC/S GMP manufacturer of human vaccines in…
The president of Adimmune Corporation discusses how the avian flu outbreak of 2006/2007 changed the course of the drug manufacturing industry in Taiwan, what that meant for Adimmune, and how…
The managing director of Burrill & Company discusses the biotech industry in Taiwan, the various hurdles the market faces and why there is so much potential for industry growth in…
TaiGen is on the brink of releasing Taiwan’s first innovative drug. In this interview, the Chairman and CEO of the company discusses the development path the company chose to take,…
An expert perspective on the possibilities of self-pay markets in Taiwan, and the opportunities afforded by bringing manufacturing of medical technology to the country, for export to the region. Uni-Pharma…
You have been in Taiwan now for ten months. What are the most important characteristics of this market from your perspective, and what surprised you most about Taiwan? Taiwan is…
A round-table discussion with leading figures from Taiwan’s NHRI, covering perspectives on the current state of the Taiwanese healthcare and pharmaceutical environment, links between academia and industry, the potential of…
The Director General of one of the world’s most successful science parks discusses the history of the park, the reasons behind its incredible success, the unique set-up of the park…
In the first part of this two-part interview, the Chairman of TTY Biopharm considers the success of his long-term strategy to streamline TTY’s portfolio and focus on the company’s strengths,…
The President & CEO of Vita Genomics talks about the advantages that genomic testing offer both to sick and healthy patients, as well as the opportunities to catalogue the science…
The President of Gene Health, a company specialized in genomics testing, talks about the current market situation for genomic testing, and building the business in the Chinese market, as well…
The General Director of the ‘Invest in Taiwan’ program discusses Taiwan’s competitiveness on a global and regional level, highlights the areas and industrial sectors where the country is looking to…
In the first of this two-part interview, the chairperson of UBI and UBI Asia explains the work that her company has done to improve the landscape for Taiwanese pharma and…
In the second part of this two-part interview, the Chairperson of UBI and UBI Asia offers her thoughts on the challenges and opportunities of the Chinese market, and explains her…
See our Cookie Privacy Policy Here
